Stock Events

Stock Events

Sagimet Biosciences 

$4.85
0
+$0+0% Thursday 03:07

Statistics

Day High
4.85
Day Low
4.85
52W High
-
52W Low
-
Volume
6
Avg. Volume
-
Mkt Cap
150.35M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

20MayExpected
Q3 2025
Q4 2025
Next
-0.43
-0.38
-0.34
-0.29
Expected EPS
-0.36851
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2021
2022
2023
2024
0Revenue
-91.13MNet Income

Analyst Ratings

$25.60Average Price Target
The highest estimate is 35.00.
From 5 ratings within the last 6 months. This is not an investment recommendation.
Buy
60%
Hold
40%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow SGMT.BOATS. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Viking Therapeutics
VKTX
Mkt Cap4.02B
Viking Therapeutics is developing therapies for metabolic and endocrine disorders, similar to Sagimet's focus on NASH (non-alcoholic steatohepatitis).
Madrigal Pharmaceuticals
MDGL
Mkt Cap12.55B
Madrigal Pharmaceuticals focuses on the development of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases, directly competing in the NASH space.
Galmed Pharmaceuticals
GLMD
Mkt Cap3.55M
Galmed Pharmaceuticals is engaged in the development of oral therapies for the treatment of liver diseases, including NASH, positioning it as a competitor.
Gilead Sciences
GILD
Mkt Cap173.41B
Gilead Sciences, with its broader portfolio, includes treatments for liver diseases such as NASH, competing with Sagimet's focus areas.
Agios Pharmaceuticals
AGIO
Mkt Cap2.06B
Agios Pharmaceuticals focuses on cellular metabolism and rare genetic diseases, including metabolic disorders, which puts it in competition with Sagimet's metabolic disease focus.

About

Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional lipid metabolism pathways. Its lead drug candidate is Denifanstat, a FASN inhibitor for the treatment of nonalcoholic steatohepatitis and acne. The company is also developing TVB-3567, a FASN inhibitor for the treatment of various types of cancers. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.
Show more...
CEO
ISIN
US7867001049

Listings

MU
DE
0O2.MU
STU
DE
0O2.STU
F
DE
0O2.F
XNAS
US
SGMT

0 Comments

Share your thoughts

FAQ

What is Sagimet Biosciences stock price today?▼
The current price of SGMT.BOATS is $4.85 USD — it has increased by +0% in the past 24 hours. Watch Sagimet Biosciences stock price performance more closely on the chart.
What is Sagimet Biosciences stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Sagimet Biosciences stocks are traded under the ticker SGMT.BOATS.
What is Sagimet Biosciences market cap?▼
Today Sagimet Biosciences has the market capitalization of 150.35M
When is the next Sagimet Biosciences earnings date?▼
Sagimet Biosciences is going to release the next earnings report on May 20, 2026.
What were Sagimet Biosciences earnings last quarter?▼
SGMT.BOATS earnings for the last quarter are -0.29 USD per share, whereas the estimation was -0.43 USD resulting in a +32.9% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Sagimet Biosciences revenue for the last year?▼
Sagimet Biosciences revenue for the last year amounts to 0 USD.
What is Sagimet Biosciences net income for the last year?▼
SGMT.BOATS net income for the last year is -91.13M USD.
In which sector is Sagimet Biosciences located?▼
Sagimet Biosciences operates in the Other sector.
When did Sagimet Biosciences complete a stock split?▼
Sagimet Biosciences has not had any recent stock splits.